olfactory receptor family 5 subfamily B member 12Genealiases: OR11-241 · OR5B12P · OR5B16 · OST743
Q-omics provides the consensus-scored OR5B12 profile across patient tissues and cancer cell-line models. OR5B12 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, OR5B12 is differentially expressed in 4, with the highest sampling consensus in HNSC. Additionally, OR5B12 RNA expression shows 6,489 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight UVM, HNSC, and STAD as cancer lineages where OR5B12 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OR5B12 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OR5B12 survival associations across molecular data types. OR5B12 RNA expression shows survival associations in the most cancer types (15), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OR5B12 RNA expression–survival associations across cancer types. High OR5B12 expression shows unfavorable associations in UVM, THYM and SCLC, but favorable associations in OV, SKCM and CHOL. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for OR5B12 RNA expression.
This table summarizes OR5B12 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for OR5B12. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OR5B12 shows lower tumor expression in KIRP and higher tumor expression in HNSC, UCEC and KIRC. The HNSC box plot shows higher OR5B12 RNA expression in tumor versus normal tissue (log2 FC = +0.067, t-test p = .003).
This table shows molecular features associated with OR5B12 in patient tissues and cancer cell lines. In patient samples, OR5B12 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, OR5B12 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and BLOOD_Lymphoma.
